Citi sees Novo Nordisk sales slightly above consensus
Citi said Novo Nordisk's third-quarter sales could come in 1% above consensus, helped by a strong Wegovy pill launch in the U.K. The bank cut its target price to 296 kroner from 310 kroner and kept a neutral rating.